Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: EigerBio Europe Ltd., 1 Castlewood Avenue, Rathmines, D06 H685, Ireland
Zokinvy 50 mg hard capsules.
Zokinvy 75 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule (capsule). Zokinvy 50 mg hard capsules: Size 4 hard capsule (5 mm x 14 mm), opaque yellow with “LNF” and “50” printed in black. Zokinvy 75 mg hard capsules: Size 3 hard capsule (6 mm x 16 mm), opaque light orange with "LNF and “75” printed in black. |
Zokinvy 50 mg hard capsules: Each capsule contains 50 mg lonafarnib.
Zokinvy 75 mg hard capsules: Each capsule contains 75 mg lonafarnib.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lonafarnib |
Lonafarnib is a disease modifying agent that prevents farnesylation, thereby reducing the accumulation of aberrant progerin and progerin-like proteins in the cell’s inner nuclear membrane. This results in maintaining cell integrity and normal function. |
| List of Excipients |
|---|
|
Capsule contents: Povidone Capsule shell: Gelatin (E171) Black ink: Shellac |
HDPE bottle, containing desiccant in a cannister and capsules, with induction seal and polypropylene cap. Pack size of 30 hard capsules.
EigerBio Europe Ltd., 1 Castlewood Avenue, Rathmines, D06 H685, Ireland
Zokinvy 50 mg hard capsules: EU/1/22/1660/001
Zokinvy 75 mg hard capsules: EU/1/22/1660/002
| Drug | Countries | |
|---|---|---|
| ZOKINVY | Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
